Antibodies, Monoclonal, Murine-Derived
"Antibodies, Monoclonal, Murine-Derived" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies obtained from a single clone of cells grown in mice or rats.
| Descriptor ID |
D058846
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.075 D12.776.124.790.651.114.224.075 D12.776.377.715.548.114.224.284
|
| Concept/Terms |
Antibodies, Monoclonal, Murine-Derived- Antibodies, Monoclonal, Murine-Derived
- Murine-Derived Monoclonal Antibodies
- Antibodies, Murine-Derived Monoclonal
- Monoclonal Antibodies, Murine-Derived
- Murine Derived Monoclonal Antibodies
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Monoclonal, Murine-Derived".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Murine-Derived [D12.776.124.486.485.114.224.075]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Murine-Derived [D12.776.124.790.651.114.224.075]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Murine-Derived [D12.776.377.715.548.114.224.284]
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Monoclonal, Murine-Derived".
This graph shows the total number of publications written about "Antibodies, Monoclonal, Murine-Derived" by people in this website by year, and whether "Antibodies, Monoclonal, Murine-Derived" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 2 | 2 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 3 | 3 |
| 2010 | 2 | 0 | 2 |
| 2011 | 0 | 2 | 2 |
| 2012 | 0 | 1 | 1 |
| 2013 | 2 | 1 | 3 |
| 2014 | 3 | 0 | 3 |
| 2015 | 1 | 1 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Monoclonal, Murine-Derived" by people in Profiles.
-
Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2017 Nov 01; 35(31):3538-3546.
-
Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. J Clin Oncol. 2017 Jul 10; 35(20):2260-2267.
-
Molecular Subtyping in Diffuse Large B Cell Lymphoma: Closer to an Approach of Precision Therapy. Curr Treat Options Oncol. 2017 02; 18(2):11.
-
Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable. Br J Haematol. 2016 Nov; 175(4):631-640.
-
The controversy of hepatitis C and rituximab: A multidisciplinary dilemma with implications for patients with pemphigus. Indian J Dermatol Venereol Leprol. 2016 Mar-Apr; 82(2):182-3.
-
Private and public coverage policies for rituximab in the treatment of immunobullous disease in the United States. J Am Acad Dermatol. 2015 Aug; 73(2):337-8.
-
A unique description of stage IV extranodal marginal zone lymphoma (EMZL) in an adolescent associated with gamma heavy chain disease. Pediatr Blood Cancer. 2015 May; 62(5):905-8.
-
Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes. QJM. 2014 Oct; 107(10):821-8.
-
JC polyomavirus granule cell neuronopathy in a patient treated with rituximab. JAMA Neurol. 2014 Apr; 71(4):487-9.
-
Nonvasculitic autoimmune meningoencephalitis after rituximab: the potential downside of depleting regulatory B cells in the brain. J Clin Rheumatol. 2014 Apr; 20(3):163-6.